SD-101-6.0 cream
Phase 3Terminated 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Epidermolysis Bullosa
Conditions
Epidermolysis Bullosa
Trial Timeline
Jun 9, 2015 → Sep 3, 2018
NCT ID
NCT02670330About SD-101-6.0 cream
SD-101-6.0 cream is a phase 3 stage product being developed by Amicus Therapeutics for Epidermolysis Bullosa. The current trial status is terminated. This product is registered under clinical trial identifier NCT02670330. Target conditions include Epidermolysis Bullosa.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02670330 | Phase 3 | Terminated |
Competing Products
13 competing products in Epidermolysis Bullosa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Efgartigimod | Argenx | Phase 1/2 | 38 |
| KB803 + Placebo | Krystal Biotech | Phase 3 | 74 |
| Topical beremagene geperpavec + Placebo gel | Krystal Biotech | Phase 1/2 | 38 |
| Topical Beremagene Geperpavec | Krystal Biotech | Phase 3 | 74 |
| Open Label Topical Beremagene Geperpavec (B-VEC) | Krystal Biotech | Phase 3 | 74 |
| SD-101 dermal cream (3%) + SD-101 Dermal Cream (6%) + Vehicle (SD-101 0%) | Amicus Therapeutics | Phase 2 | 49 |
| SD-101-6.0 cream + Placebo (SD-101-0.0) cream | Amicus Therapeutics | Phase 3 | 74 |
| SD-101 dermal cream (6%) | Amicus Therapeutics | Phase 2 | 49 |
| LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Abeona Therapeutics | Phase 1/2 | 33 |
| EB-101 | Abeona Therapeutics | Phase 3 | 69 |
| EB-101 Surgical application of RDEB wounds | Abeona Therapeutics | Phase 3 | 69 |
| VPD-737 | Vyne Therapeutics | Phase 2 | 44 |
| Serlopitant Tablet + Placebo Oral Tablet | Vyne Therapeutics | Phase 2 | 44 |